Claus Garbe, MD, of the University of Tuebingen, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss the survival of sentinel lymph node-positive melanoma patients with and without complete lymph node dissection (Abstract LBA9002).
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, and Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, discuss a form of v...
Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-r...
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival ...
For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD,
John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.
